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Introduction 
Influenza viruses cause annual epidemics throughout the world and the majority of 
deaths are seen in the elderly and in those with pre-existing chronic conditions. 
Pandemics are characterised by a high attack rate, high virulence and by major 
changes in the genetic material of the virus so that a large percentage of the population 
will have no pre-existing immunity to the virus (Abramson 2011).  
In the summer of 2009 it was clear that the novel influenza A/H1N1 virus spread 
rapidly between people. The immunity of the world's population was small and the 
risk of a pandemic was great. Norway had already experienced its first imported cases 
of the novel influenza virus, but so far below the epidemic threshold level.  
As of September 2009, it appeared that the infectivity was great, but the illness in most 
cases relatively mild. However, cases of severe outcome in young, otherwise healthy 
people, as well as in pregnant women were reported, in addition to the usual risk 
groups with chronic illness (Dawood 2009, Jamieson 2009). Older people over 65 who 
are otherwise particularly susceptible to complications associated with influenza, 
appeared to be more protected (Dominguez-Cherit 2009, Louie 2009). The 
consequences in terms of morbidity and mortality of the new virus were unknown at 
this time, and there was a great need for more knowledge about the clinical course of 
the disease. 
As part of preparations for a possible pandemic, mass vaccination of the entire 
Norwegian population was planned. There had been some discussion in the public 
about the appropriateness and potential risks of such a strategy. We wanted to explore 
opinions about risks and preventive measures among patients attending general 
practice with influenza.  
Influenza epidemics put pressure on the primary care system. The regular GP scheme 
allows GPs to have very good overview of the chronically ill in their population. This 
means that Norwegian general practice would be an excellent "laboratory" for 
studying the disease and its consequences.  
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Abstract 
Background: Primary care plays a major role in the response to a pandemic. The 
objectives of this thesis were to investigate the outbreak of the 2009 influenza 
pandemic from a primary care perspective with focus on clinical manifestations, 
behavioural measures and utilisation of services. 
Methods: Cross-sectional questionnaire and clinical observational data from patients 
in general practice diagnosed with influenza-like illness, and nationwide registry-
based studies based on claims data from general practice and out-of-hours services in 
Norway.  
Results: Pandemic influenza in general practice was characterised by symptoms of 
fever, fatigue, cough and headache of 1 week duration. Hospitalisation was reported in 
0.6% of cases and oseltamivir treatment in 39% of cases, but antiviral treatment did 
not affect the duration of illness. Women reported better adherence to personal 
protective measures and were more concerned about the side effects of the pandemic 
vaccine then men. The majority of influenza-like illness consultations took place in 
general practice as compared to out-of-hours services, however there was a 5.5-fold 
increase of influenza-like illness consultations in the out-of-hours services during the 
2009 pandemic season in comparison to the 2008-9 season. General practice increased 
its capacity in response to the increased patient surge. Young age was associated with 
attending out-of-hours services for influenza-like illness as compared to attending the 
general practitioner. Pregnancy, diabetes and chronic lung disease were significant risk 
conditions for attending out-of-hours services among patients with influenza-like-
illness during the pandemic. Contrary to this, having consultations with the general 
practitioner before the pandemic was associated with relatively lower use of out-of-
hours services in the pandemic period. 
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1. Background 
1.1 Influenza pandemics in history 
I incline to the belief that influenza is not infectious but due to some 
impurity, probably chemical, in the air, which appears to affect the 
nervous system most powerfully (…) but the whole question of the 
etiology of influenza and the mode in which it spreads is still a mystery, 
and we can only hope some light may ere long illumine the darkness that 
enshrouds it. (Nicholson 1891) 
Influenza epidemics have been documented by written sources for several hundred 
years, but there are written reports on possible influenza dating back to 412 BC (Potter 
2001). Pandemics occur at an interval of 10 to 50 years and arise when a novel avian 
influenza heamagglutinin (HA) or/and neuraminidase (NA) mixes through 
reassortment with pre-existing human influenza viruses or by an avian virus that adapt 
to effective human transmission. It is believed that pigs can serve as mixing vessels as 
they have receptors for both human and avian viruses in their epithelial cells (Peiris 
2009). Three influenza pandemics were recognised in the 20th century: in 1918–19, 
1957 and 1968. The H1N1 influenza pandemic in 1918-19, also called the “Spanish 
flu” had a fatality rate of 2-3%, and caused between 40 and 50 millions deaths due to 
the high number of infected (Potter 2001). Nearly half of influenza-related deaths 
during the Spanish flu were in age group 20-40 years and among otherwise healthy 
individuals (Simonsen 1998). The reason for the high mortality in the young is not 
fully understood. The shift in mortality rates towards younger age in pandemics 
compared to seasonal epidemics is suggested to be due to exposure to related viruses 
in previous pandemics thus sparing those at older age (Miller 2009). It is estimated 
that up to 50% of the world’s population was infected during the “Spanish flu” (Potter 
2001). The “Asian flu” in 1957-58 was of H2N2 subtype, and mostly affecting 
children. A fatality rate at <0.2% (1-4 million deaths) has been calculated. However, 
elevated mortality rates in children did not occur (Webster 2013). The pandemic in 
1968-69, the “Hong Kong flu” was of H3N2 subtype and affected all age groups 
(WHO 2011a). The 1968 pandemic was relatively mild probably due to pre-existing 
antibodies of the H2N2 seasonal strain that gave some protection in the elderly 
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(Webster 2013). The re-emergence of the A(HIN1) virus in 1977 to cause the “Russian 
flu”, has not been considered to be a true pandemic, as the virus probably was 
introduced to the population from a laboratory stock (Webster 2013).  
1.2 Influenza viruses 
There are three types of influenza virus: A, B and C. They all belong to the 
Orthomyxoviridae family of viruses. Influenza C rarely causes disease in man. 
Influenza A and B are considered to be the major human pathogens responsible for 
seasonal influenza. While type B causes occasional outbreaks and seasonal epidemics, 
type A is the only type of virus associated with pandemic influenza. Influenza virus A 
is the most important of all influenza types and it is found in a large range of animal 
species (birds, pigs, horses, mink, seals, whales). The type A is divided into several 
subtypes based on the properties of the surface proteins HA and NA. The HA is 
responsible for binding and entry into host epithelial cells while the NA is involved in 
the process of new viral particles budding out of host cells. Birds form the natural 
reservoir for all known influenza A subtypes (Abramson 2011).  
There are 18 HA subtypes and 11 NA subtypes known to date (Freidl 2014). Only H1, 
H2 and H3 heamagglutinins and N1 and N2 neuraminidases subtypes are known to 
have caused pandemic human disease. Avian subtypes H5, H7 and H9 can 
sporadically infect humans and cause disease (Broberg 2014, Freidl 2014, Van-Tam 
2009). The HA and NA surface proteins are genetically unstable and cause changes in 
the virus over time.  
“Antigentic drift” is the term used to describe point mutations that lead to small 
variations in the HA and NA proteins. Antigenic drift results in sporadic outbreaks and 
seasonal epidemics due to partial escape in host immunity. The HA and NA proteins 
are closely related to previous circulating seasonal influenza virus, but as the surface 
proteins change slightly over time by antigenic drift previously acquired immunity 
does not work, making the population more prone to infection; hence the need for 
updating the influenza vaccine at a yearly basis (Temte 2010). “Antigenic shift” is 
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used to describe recombinant genetic changes in the surface proteins HA and NA that 
lead to production of a new strain, i.e. a new genetic variant of the virus. Antigenic 
shifts cause more widespread epidemics and pandemics due to lack of immunity in a 
large percentage of the population (Abramson 2011). 
Influenza viruses spread by droplets from the airways of an infected individual, but 
there is also evidence that influenza can spread by contact with body fluids such as 
blood, faeces and vomit or by touching contaminated surfaces (Arena 2012, Webster 
2013). The incubation period from infection to first appearance of symptoms varies 
from 1-4 days. The illness usually lasts less then one week. Children are more likely to 
transmit the virus due to higher levels of virus load in their respiratory tract and lower 
adherence to personal hygienic measures. Also, they are often in crowded 
kindergartens and schools that make the transmissibility easier. The virulence is 
highest during the febrile phase of disease and subsides steadily over 5-7 days (longer 
in children). Most cases of influenza are self-limited and patients normally recover 
without sequelae. Complications, such as pneumonia, bronchitis, otitis media and 
other secondary bacterial infections are more common in people with underlying co-
morbidity, in children and among the elderly (Meier 2000, Webster 2013). 
1.2.1 Epidemiology 
The virologic basis for recurrent epidemics is a continual process of antigenic drift 
among circulating influenza viruses occurring annually in temperate regions 
(Simonsen 1998). Usually one influenza A virus (H1N1 or H3N2 since 1977) or 
influenza B virus will dominate each winter season, but mixed epidemics do occur 
(Simonsen 1997). Influenza epidemics are remarkably seasonal in character. Most 
epidemics in the southern hemisphere peak at local mid-winter (May-September) and 
correspondingly epidemics in the northern hemisphere peak around winter 
(November-March). The influenza activity around tropical zones is more diverse 
(Hope-Simpson 1981). Low temperature and low absolute humidity are factors that are 
identified to explain the seasonality of influenza epidemics in temperate areas (Lowen 
2014, van Noort 2012). Low absolute humidity is found to be associated with 
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increased influenza mortality, also after controlling for low temperature (Barreca 
2012). There is scarce data on the effect of weather in tropical and subtropical 
countries. One report found a temporal association between low temperature and high 
level of influenza-like illness (ILI) cases in Niger (Jusot 2012). Epidemics tend to start 
in the eastern or southern hemispheres and then spread to Europe and North America. 
Pandemics however do not follow the rule of seasonality. The 1918, 1957 and 2009 
pandemics started in spring, had several waves and spread globally. High influenza 
activity was observed year-around (Potter 2001). The Textbook of Influenza 
characterises a pandemic virus as a novel influenza A virus with animal origin that 
causes human disease with sustained human-to-human transmission, to which most or 
all of the population lack immunity (Webster 2013). 
Influenza mortality is difficult to estimate based on influenza-specific diagnoses alone, 
as this will certainly underestimate the true burden of influenza. Mortality due to 
secondary complications such as bacterial infection and exacerbations of chronic 
diseases succeeding the influenza infection should be taken in to account when 
estimating influenza mortality. Therefore influenza mortality traditionally has been 
estimated through an excess mortality approach (Webster 2013). The estimated 
influenza-related excess mortality in Norway for the influenza seasons from 1976 to 
2004 varied from 217 to 1802 deaths, which corresponds to a mean estimated excess 
influenza-related mortality of 910 deaths per season, or 2.1% of all deaths per year 
(Gran 2010). In the USA, the estimated excess mortality due to influenza during 
seasons 1972-2002 was 21,000 deaths per year on average (Simonsen 1997). Highest 
mortality was seen in persons >65 years and in seasons where influenza A/H3N2 was 
the dominating virus had the highest mortality. The reason for this severe impact on 
mortality when the A/H3N2 virus was the dominating seasonal strain is believed to be 
because this virus type have been resulted from major drifts thus making a larger 
proportion of the population without pre-existing immunity (Simonsen 1998, Webster 
2013).  
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The 2009 influenza pandemic 
Influenza pandemics occur when an influenza virus with a novel HA, against which 
there is little or no existing immunity, emerges in the human population and efficiently 
transmits from human-to-human (Garten 2009). The A(H1N1)pdm09 virus is a 
quadruple reassortant virus containing genetic materials from human, avian and swine 
influenza viruses with genetic segments from the Eurasian swine linage, classic swine 
H1N1 lineage, human H3N2 lineage and avian lineage (Dawood 2009). The first cases 
of human infection were detected in Mexico in March 2009 (WHO 2009a). On 11 
June 2009, WHO raised the level of pandemic alert from phase 5 to phase 6 (highest 
level), indicating that the first influenza pandemic in the 21st century was under way 
(WHO 2009b). At this point 74 countries had reported 28,774 cases of laboratory 
confirmed pandemic influenza, including 144 deaths. In total, 18,500 deaths were 
registered during the pandemic due to A(H1N1)pdm09. The true burden of the 
pandemic is difficult to interpret, as many cases are not confirmed by laboratory tests 
or in death certificates. The highest attack rates were seen in children and young 
adults, and only 2% of the confirmed cases were in the age group ≥65 years of age 
(Devaux 2010, Waalen 2010). It is presumed that the immunity among older age 
groups was related to pre-existing antibodies as a result of previous exposure to 
genetically related H1N1 viruses (Miller 2010, Waalen 2010).  
During the 2009 pandemic, the estimated excess influenza mortality in the USA was 
12,500 deaths from April 2009-April 2010, and 87% of deaths were in the age group 
below 65 years of age (Shrestha 2011). Estimated excess deaths during the 2009 
pandemic in Denmark range from 30 to 312 (0.5–5.7 per 100,000 population) (Molbak 
2011). Globally, it was estimated that 151,700–575,400 respiratory and cardiovascular 
deaths were associated with the 2009 influenza pandemic (Dawood 2012). In Norway, 
the pandemic influenza mortality was 56-96 excess deaths depending on the method 
applied. Most of excess deaths were observed in age group +65 years (Gran 2013). 
The first two cases of confirmed influenza in Norway were detected 9 May 2009, both 
cases infected during a stay in Mexico. The health authorities in Norway have 
estimated that 900,000 individuals were infected during the pandemic in Norway 
 17 
(Kacelnik 2011). There were 12,513 laboratory confirmed cases and 32 deaths in the 
country. The majority of fatal cases had underlying co-morbidity (Kacelnik 2011). 
Among hospitalised patients to a Norwegian university hospital, 86% had underlying 
co-morbidity (Brandsaeter 2011). Norway had two waves of ILI. A minor epidemic 
occurred in July-August, were rhinoviruses co-circulated together with influenza, 
causing the small summer wave (Anestad 2011, Waalen 2010). The main wave 
occurred in October-November and the peak was observed in week 45, 2009 (Blasio 
2012, Waalen 2010). This two-wave pattern was seen in many European countries 
(Keramarou 2011, Molbak 2011).  
In preparation for a pandemic, the Norwegian Medical Association and the Norwegian 
Directorate of Health in a joint press release on 9th of September 2009, suggested a 
number of measures to make the health care services better able to meet the increased 
demand for medical services and mass vaccination. Among these proposed measures 
were extended opening hours for GPs, opportunities for recruitment of additional 
personnel, increased use of self sickness-certification and reprioritisation of doctor's 
appointments (Braaten 2009, Helsedirektoratet 2009). The specific measures were 
authorised by the Norwegian Directorate of Health at the following dates: The sick 
leave self-certification was extended from 3 to 8 days and launched on 23rd of October 
2009. On the 5th of November 2009 oseltamivir and zanamivir were released as over-
the-counter drug without doctor’s prescription to ease the pressure on the primary care 
services (Blasio 2012). 
1.2.2 Nomenclature 
The nomenclature designates the type/animal host/geographical place of 
isolation/strain number/year of isolation (two of four digits), and if type A, followed 
by bracket with H and N subtypes (Van-Tam 2009). The pandemic influenza virus that 
caused the 2009 pandemic was isolated in California and had the following 
nomenclature: A/swine/California/7/2009 (H1N1). In 2011 the official name for the 
pandemic strain was changed to A(H1N1)pdm09 (WHO 2011b).   
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1.2.3 Clinical signs and symptoms  
Seasonal influenza presents as an acute illness characterised predominantly by cough, 
malaise and fever. Other common symptoms are chills, headache, anorexia, rhinitis 
and sore throat (50-79% of confirmed cases), sputum, dizziness, hoarseness and chest 
pain (<50% of confirmed cases) and gastrointestinal symptoms (vomiting, diarrhoea, 
nausea, stomach pain) (<10% of confirmed cases) (Van-Tam 2009). The clinical signs 
and symptoms of pandemic influenza were found to be similar to previous seasonal 
influenza epidemics except that children and young adults were disproportionately 
affected by the A(H1N1)pdm09 as only 2% of laboratory-confirmed cases were <65 
years of age (Belongia 2010, Ong 2009). Studies from the first cases of pandemic 
influenza in the USA, United Kingdom and surveillance data from the first wave in 
Europe, reported that up to 1/4 of patients with confirmed influenza had 
gastrointestinal symptoms (diarrhoea, vomiting, stomach aches and nausea), especially 
among young children (Dawood 2009, Devaux 2010, McLean 2010). Other reports did 
not confirm these results (Cao 2009, Chan 2010, Ong 2009). 
1.2.4 Diagnosis of influenza 
Laboratory diagnosis 
The viral load in the respiratory tract is highest during the acute phase of the influenza 
disease. For seasonal influenza A and B and A(H1N1)pdm09, viral shedding peaks 
within days of the onset of the illness. Figure 1 illustrates the clinical phases of 
influenza and eligible diagnostic tests according to time of illness. Specimens intended 
for virus isolation and for viral genome detection should be collected as soon as 
possible after the onset of symptoms when the viral load is highest. Laboratory tests 
for diagnosis of acute phase illness include reverse transcriptase polymerase chain 
reaction (RT-PCR) assay, viral culture, enzyme-linked immunoassay (EIA), 
immunofluorescence (IF) and point of care test (PoCT) (Webster 2013).  
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Figure 1. Influenza detection according to phases of illness using different 
diagnostic tests: Reverse transcriptase polymerase chain reaction (RT-PCR) 
assay, virus isolation, enzyme-linked immunoassay (EIA), 
immunofluorescence (IF), point-of-care test (PoCT) and antibody detection 
(Webster 2013). 
 
The WHO recommended molecular diagnostics (RT-PCR) to be the “gold standard” 
for diagnosing A(H1N1)pdm09 (WHO 2009c). The RT-PCR test can distinguish 
between different subtypes of influenza and the test result is usually ready in 1-2 days 
depending on the capacity of the laboratory, logistics and transport. Point-of-care tests 
(rapid influenza antigen immunoassay) have also been developed, but the usefulness 
of those test kits is questionable as the sensitivity is low (Poeppl 2011).  
Serologic tests rely on the detection of antibody immune response to the influenza 
infection. Serological testing is not useful in a clinical setting as it is necessary to 
obtain sera in the acute phase of the disease (baseline level) and 10-14 days post 
illness onset to be able to detect raise in titre (Hobson 1972). However, it is useful for 
population studies and to evaluate vaccine efficacy (Madhun 2010). When a novel 
influenza A virus arise in the community (i.e. a pandemic strain) in which a large part 
of the population has little or no previous immunity to the new strain, a single blood 
sample is sufficient to detect rise in titre level as evidence of recent infection to that 
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virus. The hemagglutination inhibition (HI) antibody tests can detect strain-specific 
serum IgG HI titres. Titres ≥40 are considered 50% protective and titres ≥10 as 
seropositive (Morner 2012).   
Clinical diagnosis 
Different diagnostic criteria have been developed to identify influenza on a clinical 
basis. Clinical diagnosis of influenza is challenging, however, because these symptoms 
are shared with many other common respiratory tract infections (van Elden 2001). The 
presence of fever (> 38°C) and cough when the prevalence of influenza is high in the 
community has been shown to give the best prediction of influenza, with a positive 
predictive value of 30-80% for influenza diagnosis (Govaert 1998, Michiels 2011, 
Monto 2000, van Elden 2001). Outside the influenza season, the absence of cough and 
fever makes the diagnosis very unlikely (Michiels 2011).  
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1.2.5 Clinical risk groups and vaccine recommendation 
Yearly influenza vaccination to high-risk groups and the elderly has been 
recommended for decades in the United States and many other countries (Couch 
2000). There is remarkable consistency internationally concerning targeted risk groups 
and vaccine recommendations (Mereckiene 2014). Most countries recommend 
vaccination for all individuals ≥65 years of age (some countries at age 50, 55 or 60 
years of age). The Norwegian recommendation is given in Table 1.   
 Table 1. Seasonal influenza vaccine recommendation in Norway – season 2013-4  
Everyone aged 65 years and over 
Residents in nursing homes and sheltered accommodation 
Pregnant women after week 12 of pregnancy (2nd and 3rd trimester) 
Children and adults with:  
 diabetes mellitus, type 1 or 2 
 chronic respiratory disease 
 chronic cardiovascular disease 
 chronic liver failure 
 chronic renal failure 
 chronic neurological disease or injury 
 impaired immunity against infection 
 severe obesity (BMI over 40) 
 other severe or chronic illness evaluated on an 
individual basis by a doctor 
Health professional with patient contact 
Pig farmers and others who have regular contacts with live pigs 
Household contacts of highly immunosuppressed patients should consider 
vaccination against influenza to protect the patient 
(Norwegian Institute of Public Health 2014a) 
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Vaccine efficacy 
The evidence of effectiveness of seasonal influenza vaccination derives mainly from 
observational studies as few clinical studies and randomised control trials have been 
performed to evaluate this (Govaert 1994, Vist 2009). In a multicentre case-control 
study performed in the 2012-3 season to measure the effect of the seasonal vaccine, 
the effectiveness for preventing medically attended laboratory-confirmed influenza 
was below 70% (Kissling 2014). The Norwegian Knowledge Centre for the Health 
Services concluded in a review in 2009 that the seasonal influenza vaccine may 
possible reduce the risk of ILI in the elderly, however the documentation was scarce 
and affected with high risk of bias (Vist 2009). In a bias-adjusted meta-analysis of 14 
cohort studies, influenza vaccination of community-dwelling persons ≥60 years, 
showed statistically significant effectiveness against hospitalisation from influenza 
and/or pneumonia and all-cause mortality, but not against influenza and ILI 
(Darvishian 2014). In a population-based cohort study from Sweden, the vaccine 
effectiveness in terms of reducing all-cause mortality in three influenza seasons was 1-
19% (Ortqvist 2007). A study from Korea with a retrospective case-control design 
found a vaccine effectiveness of 32.5% in preventing hospitalisations, but the 
effectiveness rose to 72.6% among patients ≥65 years with chronic heart disease (Seo 
2013). Influenza vaccination in healthy adults seems to have no effect on reducing 
hospitalisation or complications such as pneumonia, and only modest effect on 
reducing influenza symptoms (Demicheli 2014). 
Influenza vaccination and clinical risk groups 
Patients with diabetes have increased risk of influenza-related complications and the 
increased risk is explained by abnormal glucose metabolism (Frasca 2013, Wang 
2013). Lau et al. found a reduction of 43% of pneumonia and influenza-related 
hospitalisations in adult diabetic patients after influenza vaccination compared to 
unvaccinated matched controls (Lau 2013). Influenza vaccination is reducing 
hospitalisations and mortality among patients with cardiovascular diseases and chronic 
lung diseases (Nichol 2003, Simpson 2010). Morbid obesity (BMI≥40) has been 
detected as a novel risk factor for severe influenza outcome after infection with 
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A(H1N1)pdm09 (Schreter 2011, Yu 2011). The increased risk among obese is related 
to impairment of the immune system due to defects in T cell function (Paich 2013). 
Pregnant women also had increased risk of influenza-related complication after 
infection with A(H1N1)pdm09, probably due to altered immunity and physical 
adaptation during pregnancy (Jamieson 2009, Lim 2011). A(H1N1)pdm09 infection in 
pregnancy was associated with increased risk of foetal death (Haberg 2013) and 
maternal immunization has been proven effective in reducing influenza-related 
complications in the offspring (Zaman 2008) but no effect on reducing abortion or 
foetal death (Demicheli 2014). 
Influenza vaccines 
The seasonal influenza vaccine nowadays usually contains inactivated surface antigens 
of HA and NA for the three seasonal circulating strains. An increase of serum 
concentration of antibodies to one subtype of HA is used as a measure of the 
protection offered against viruses of the same subtype. Cellular immunity is also 
contributing to the immune responses against influenza, and it is speculated that those 
who are vaccinated have less cytotoxic T-cell activity than those who are naturally 
infected by influenza viruses. For this reason is it debated whether healthy individuals 
and health care workers should be targeted groups for annual influenza vaccination 
(Haneberg 2013).  
The influenza vaccine is updated on a yearly basis based on circulating strains. 
Antibodies against the surface protein HA are of major importance for protection 
against infection, and the HA is the primary component of the currently licensed 
influenza virus vaccines (Garten 2009). The 2014-5 seasonal influenza vaccine 
(northern hemisphere) contains HA surface antigens of influenza A/H1N1, influenza 
B, and influenza A/H3N2. For the 2013-4 season the vaccine effectiveness has been 
reported to be 40-73% in preventing H1N1 influenza (Andrews 2014, Castilla 2014). 
The pandemic vaccine was however produced as a monovalent split virus vaccine 
containing HA of A/California/7/2009-like virus (H1N1). The two pandemic vaccines 
available (Pandemrix® and Arepanrix®) contained adjuvans (proprietary oil-in-water 
emulsion system) called AS03 to induce effective immune responses (Madhun 2010). 
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In Norway a mass vaccination campaign started in October 2009, and 40-45 % of the 
population was vaccinated with Pandemrix® (Blasio 2012, Waalen 2010). The 
effectiveness of the pandemic vaccine, measured as preventing medically attended, 
laboratory confirmed A(H1N1)pdm09 illness was 93% in a Canadian case control 
study (Skowronski 2011). In a Norwegian university hospital, 98% of health care 
workers had protective titers 2-3 weeks after vaccination with Pandemrix® (Madhun 
2010).  
There are concerns about serious side effects of the pandemic vaccine. A sudden 
increase in the rare neurological disease narcolepsy has been observed in several 
countries among children and young adults after the pandemic (Heier 2013, Miller 
2013). It is suggested that this condition was associated with Pandemrix® vaccination. 
The Pandemrix® vaccine-associated risk of narcolepsy in children and adolescents has 
been reported to be four to 13-fold compared to unvaccinated individuals (Partinen 
2014). The mechanism behind the increased risk of narcolepsy after vaccination with 
the AS03 adjuvant pandemic vaccine is not fully understood. It is suggested that the 
combination of viral particles and the adjuvant may have elicited an autoimmune 
reaction in susceptible individuals (Heier 2013).  
1.2.6 Antiviral treatment 
The neuraminidase inhibitors oseltamivir and zanamivir are commonly used drugs 
against seasonal and pandemic influenza. They work by interfering with the release of 
viral particles from the surface of epithelial cells in the respiratory tract (Abramson 
2011).  
Oseltamivir was first approved in USA in 1999 and then in Europe in 2003. Kaiser et 
al. published a paper on the treatment effects of oseltamivir in 2003 based on the 10 
randomised control studies in the oseltamivir trial. This study showed that oseltamivir 
reduced hospitalisation by 59%, reduced antibiotic use by 27% and lowered the risk of 
respiratory tract infections by 55% in healthy adults and in high-risk patients (Kaiser 
2003). Since that time oseltamivir has been stockpiled in many countries world wide 
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in the preparedness for a pandemic. It was also put on the WHO’s list of essential 
drugs (and still is) and oseltamivir was recommended for both prophylactic use and 
treatment of influenza (Jefferson 2014a). In 2009, in the light of the emerging 
pandemic, the Cochrane group attempted to make an updated review on anti-influenza 
drugs. It then became evident that the Kaiser study had serious shortcomings including 
high risk of bias, missing data and insufficient information on inclusion and exclusion 
criteria (Cohen 2009). After more than 3 years, the pharmaceutical company Roche 
finally released the full clinical data material on the oseltamivir trial to be analysed by 
the Cochrane group. After receiving the full study protocol from the Tamiflu® 
(oseltamivir) clinical trials, the Cochrane review was updated. Jeffersen et al. found a 
high level of bias in those industry-funded studies (Jefferson 2014c). According to this 
updated review, the potential benefit of oseltamivir is probably limited to a symptom-
reducing drug (Jefferson 2014b). Hsu et al. performed a systematic review of 
observational studies on treatment effects of anti-influenza drugs in 2012. They found 
that oseltamivir and zanamivir may reduce symptom duration by 33 and 23 hours 
respectively, but as seen with the randomised control trials, the evidence was limited 
due to bias (Hsu 2012). Another systematic review could not find additional treatment 
effects for zanamivir (Michiels 2014).  
In Norway, oseltamivir is approved for children and adults and zanamivir for persons 
≥5 years of age. Oseltamivir is given orally and zanamivir as an inhaled powder-
formulation. In the national guidelines from Norwegian Institute of Public Health it is 
recommended that the antivirals are to be taken within 48 hours after debut of 
influenza symptoms, but should also be considered for patients with symptoms of >48 
hours duration when there is risk of severe complications and for patients hospitalised 
with influenza. Elderly (≥65 years) and individuals with risk of severe outcomes or 
belonging to a clinical risk group are targeted groups for antiviral treatment. 
Prophylactic treatment with oseltamivir is indicated for unvaccinated close contacts 
belonging to risk groups for complications. 
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1.2.7 Influenza surveillance  
Most developing countries have a surveillance system for influenza. In Europe, 
(among them, Norway) give annual reports on epidemiology of communicable 
diseases of public health significance to the European Surveillance System. Influenza 
epidemiology (virological data and ILI consultations from primary care) is monitored 
through the European Surveillance Influenza Network (Amato-Gauci 2011). In 
Norway, the Norwegian Institute of Public Health organises this surveillance by the 
means of the Norwegian Notification System for Infectious Diseases. Selected GP 
practices have for many years been reporting the numbers of ILI to this system. From 
1998, a system of 201 sentinel GP practices was established, with weekly reporting of 
the number of ILI. These practices comprised about 10 % of all general practices of 
the former reporting system but about 25 % of the reported volume of ILI. The 
sentinels report weekly, from week 40 in autumn to week 20 in spring, the number of 
ILI using the case definition of “R80 Influenza” from the ICPC-2 (Gran 2010). During 
the pandemic season in 2009, this sentinel surveillance of ILI was extended to year-
around reporting. From 2014, this will be replaced by a new primary care surveillance 
system, called the “Disease pulse”. In this system, all consultations on a national level 
containing diagnosis “R80” from both general practice and OOH services will be 
registered in a weekly report (Norwegian Institute of Public Health 2014b). 
Virological surveillance of influenza is also performed by another system of selected 
GPs (“lighthouse GPs”) collecting nasopharyngeal swabs from ILI patients to the 
regional microbiological laboratories that in turn report to Norwegian Institute of 
Public Health. Sentinel GP surveillance system are common in many countries in 
Europe (Vega 2013). In the USA, claims data has been shown to follow the same 
trends in influenza activity as the official sentinel practices (Viboud 2014). There are 
also promising results concerning the use of medical records from OOH services for 
surveillance of influenza activity. A study from Ireland showed that ILI activity at 
OOH services peaked one week before the national rates (Brabazon 2010).  
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1.2.8 Personal protective measures to prevent influenza virus 
spreading 
Personal protective measures include improved personal hygiene (frequent hand 
washing, cover sneezes and coughs), physical protective measures (use of gloves, face 
masks and mechanical filter respirators) and social distancing (avoiding public 
transportation, crowds and work place). Adherence to personal protective measures 
has been associated with female gender (Lin 2011, Timpka 2014, Wong 2011) and 
older age groups (Bults 2011, Kiviniemi 2011, Lin 2011). Increased attention to hand 
washing was the most commonly protective measure reported during the pandemic, 
while use of face masks was the least commonly reported measures across different 
populations (Kiviniemi 2011). The evidence for face masks being protective in 
reducing influenza virus spread is limited (Cowling 2010b). In Norway, there was a 
decrease in cases of several types of infectious diseases attending the OOH services 
after the main pandemic wave succeeding the Norwegian health authorities’ campaign 
for better hygiene (Sandvik 2011). The hygiene campaign may have contributed to 
this. A population-based survey from Norway in 2007 showed that 80% of the 
respondents would take precautions concerning personal hygiene if a pandemic occurs 
in the future (Kristiansen 2007). The evidence that hand washing reduces the spread of 
infectious diseases is solid (Jefferson 2011).  
1.2.9 Attitudes towards influenza vaccination and influenza disease 
Targeted groups for influenza vaccine are people belonging to a clinical risk group, 
elderly, pregnant women and health care workers (Mereckiene 2014). Attitudes 
towards influenza vaccination vary among different populations, with age, gender and 
education level, with previous influenza vaccination uptake as well as other patient’s 
characteristics (Peretti-Watel 2013). Variation in attitudes towards vaccination is also 
seen among different types of health care workers (Fatiregun 2012, Kissin 2011, Mak 
2013). Having received the seasonal influenza vaccination in the 2008-9 season was 
the strongest predictor to receive pandemic influenza vaccination among health care 
workers (Hothersall 2012, Kaboli 2010, Toh 2012, Virseda 2010, Wong 2010). A 
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positive attitude to receive pandemic influenza vaccination is more likely among 
doctors than nurses (Arda 2011, Kaboli 2010, Toh 2012). Worries about side effects of 
the pandemic vaccine are high among health care workers in general and specifically 
among nurses (Arda 2011, Kaboli 2010, Savas 2010). The vaccination coverage 
among students is low and female gender is associated with higher perceived risk of 
getting influenza and they also show a more positive attitude towards vaccination 
(Park 2010, Suresh 2011). In the general population, factors that are associated with 
willingness to take the pandemic influenza vaccine are high perceived risk of getting 
ill and a positive attitude towards vaccine safety (Lin 2011, Naing 2012). Among 
pregnant women, pandemic vaccine receipt was associated with previous seasonal 
influenza uptake, perceived risk of getting ill and correct knowledge about the 
influenza pandemic (Eppes 2013). A major reason for declined vaccination in 
pregnancy was concerns about vaccine safety (Ding 2014, White 2010). GPs in an 
Australian study demonstrated low level of confidence to give the pandemic influenza 
vaccine to pregnant women due to precautions about vaccine safety (Maher 2014).  
1.3 The Norwegian primary health care system 
1.3.1 Organisation 
The municipalities organise general practice and OOH services in Norway. Every 
citizen has the right to be registered with a specific GP. The list system was 
established in 2001, but there has been a long tradition for personal doctoring in 
Norway (Hjortdahl 1989). 99.6% of the population has a designated GP (The 
Norwegian Directorate of Health 2014). The average list length was 1180 in 2009 and 
typical GP worked 4 days a week (30 hours) with direct patient contact (Hetlevik 
2012). Average waiting time was 6 working days in 2004 (Hetlevik 2004). GPs 
generally pre-book appointments and have a few slots available for new or urgent 
illnesses each day. The accessibility for urgent calls and emergency visits is 
challenged by a large variation between practices (Sandvik 2012a). GPs are 
responsible for primary care emergency services during office hours, but in the larger 
cities separate institutions of emergency services also operate at office hours. Primary 
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care physicians staff these services. The OOH services are organised with GPs in 
rotas. OOH services are operating evenings, nights, weekends and holidays. Several 
OOH services are organised in large inter-municipal collaborations. Only half of GPs 
working in the regular GP scheme in Norway are doing OOH work (Sandvik 2012b). 
The diagnosis system in Norwegian primary care is ICPC-2 (Brage 1996).  
1.3.2 Financing of primary care services 
GPs are paid by a combination of fixed capitation and fee-for-services. Patients pay a 
user fee for each consultation or service at the GP office. Once the patients have paid a 
certain amount in user fees, they are entitled to a healthcare exemption card. This 
amount was 2105 NOK in 2014. The fees are regulated at a yearly basis. The income 
for doctors at OOH services is by fee-for-services solely. The municipalities cover all 
other costs (ancillary staff, housing, medical equipment) at the OOH services. All 
primary care doctors working in general practice or at OOH services are obliged to 
deliver electronic billing claims to the Norwegian Health Economics Administration 
(HELFO) for reimbursement. The claims contain diagnoses according to ICPC-2, 
date/time of contact, patient’s variables, and the fees.  
1.3.3 The GP as a the primary source of medical care 
Primary care is characterised by being comprehensive, patient focused, coordinated 
and first contact access for each new need (Starfield 2005). Referral from primary care 
(both in-hospital and ambulatory specialist care) is mandatory in Norway to get to 
secondary care. Hence, GPs in Norway act as gatekeepers and coordinate access to 
more advanced care. Unlike many other countries, GPs in Norway also have an 
important role in initial care for emergency patients (Lillebo 2013). Continuity of care 
in general practice, which implies that individuals use their GP as the primary source 
of care over time for most of their health care needs, is associated with greater 
satisfaction, better compliance, and lower hospitalisation and OOH services use 
(Hjortdahl 1992, Starfield 2005). These core concepts of primary care are highly 
appreciated by GPs in different countries (Stokes 2005). A recent study from Norway 
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found that continuity of care was associated with reduced hospitalisations and use of 
specialist services (Hansen 2013). In the USA, continuity of care was associated with 
reduced cost, reduced hospitalisation rate and less adverse effect for patients with 
diabetes, heart disease and obstructive lung disease (Hussey 2014). The mean annual 
consultation rate is 2.52 in Norway (2009) and 78% of patients had at least one annual 
consultation with their regular GP (Hetlevik 2012). 
Care for people with chronic disease 
GPs are important in providing care for people with chronic diseases. Multimorbidity 
maybe defined as two or more chronic diseases or chronic conditions (Barnett 2012). 
The prevalence of patients with multimorbidity was 23% in a large study from primary 
care practices in Scotland (Barnett 2012). Prevalence figures from primary care in 
Spain was 47% (Foguet-Boreu 2014) and 32% in Denmark (Moth 2012) but the 
prevalence of multimorbidity was 66% among primary care patients >55 years in 
Ireland (Glynn 2011). Regular contact and scheduled follow up appointments with the 
GP can be preventive as early disease exacerbations can be recognised and adequate 
treatment given. Disease exacerbations among persons with cardiovascular diseases, 
chronic lung diseases, and conditions where immunodeficiency may be a part 
(diabetes, liver disease, cancer) are sensitive to exposures to infectious diseases, such 
as influenza. People with chronic respiratory diseases are frequent attenders of primary 
care (Santus 2012). Glynn et al. found significantly increased health care utilisation 
among patients with multimorbidity (Glynn 2011). A study from Australia found 
regular GP contact to be associated with reduced mortality and hospitalisation in 
patients with chronic lung diseases (Einarsdottir 2010). People with chronic diseases 
also are heavy users of the OOH services, either due to exacerbation of the chronic 
disease or due to a new unrelated event (Flarup 2014).  
The role of GPs in influenza epidemics 
In countries with a primary care system, GPs take a great responsibility during 
influenza epidemics (Bocquet 2010, Sauro 2006). GPs play a key role in the 
preparedness to an influenza epidemic as they have information about patients 
belonging to a clinical risk group and to whom influenza vaccination should be offered 
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(Collins 2008). Vaccination to people at risk can reduce the pressure on the primary 
care system in terms of reduced consultation rates (Tacken 2004). The 2009 pandemic 
caused an increase in workload for GPs; A 58% increase in consultations to primary 
care services due to influenza was reported in a region in Spain (Aldaz 2011). As most 
cases of influenza are self-limited and treated only by GPs, they play an important role 
for the vast majority of patients during outbreaks. Few patients are in need of hospital 
care. Furthermore, GPs are also important gatekeepers when patients are in need for 
more advanced care, i.e. hospitalisation or to whom a thoroughly follow up approach 
should be delivered (Lee 2010). GPs are important health counsellors, as most people 
get the usual care from a GP. An important task for GPs is also to explain to people the 
benefits of the vaccine. Scheduled meetings between the GP and the patient can offer a 
good opportunity to raise questions about vaccine recommendation and safety issues in 
a trustful manner (Kunin 2013). 
Pandemic preparedness plan – the role of the municipalities 
Every municipality in Norway has a Chief Municipal Medical Officer who is in charge 
of the community health services. In addition there may be a designated Chief 
Infection and Control Doctor who is given responsibility for surveillance of 
communicable diseases and vaccination issues. Contingency plan for mass vaccination 
in municipalities is rooted in the Act relating to the municipal health services, Act 
relating to control of communicable diseases and Act on health and social 
preparedness and associated regulations (Folkehelseinstituttet 2008). The Ministry of 
Health and Care Services is the supreme responsible organ in Norway for the plan for 
mass vaccination against pandemic influenza in municipalities together with The 
Norwegian Institute of Public Health. All municipalities in Norway are obliged to have 
a local plan for mass vaccination in preparedness for influenza pandemic. Planning for 
a pandemic is based on experience with yearly influenza vaccination. The GPs have a 
central role in the process of vaccination, as they possess the best information about 
those patients belonging to a clinical risk group (Johannessen 2009). The plan 
regulates all logistics issues concerning distribution, storing, delivery and registration 
of the vaccines. The plan should also give detailed information about how a mass 
vaccination should be organised at the community level. Small municipalities may 
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choose to organise this solely at the GPs’ offices, others by invitation in local media 
for mass vaccination in local premises such as health centres, sport halls, premises 
used for elections and so on (Rørtveit 2011). Health care workers who have direct 
patient-contact are prioritised first for pandemic influenza vaccination according to the 
national pandemic plan.  
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2. Aims 
The aim of the present thesis was to investigate the outbreak of pandemic influenza 
from a primary care perspective with focus on clinical manifestations, behavioural 
measures and utilisation of services. The three studies conducted had the following 
specific aims: 
Study I: (i) to investigate symptoms and clinical course among patients diagnosed with 
ILI in general practice; (ii) to explore whether symptoms could be differentiated 
between serologically negative and positive cases; and (iii) to investigate patients’ 
attitudes towards vaccination and their use of health preventive measures (Paper I). 
Study II: (i) to investigate how and to what extent general practice and OOH services 
were used during the 2009 pandemic in Norway; (ii) to investigate the impact of the 
pandemic on primary care services in comparison to a normal influenza season; and 
(iii) to investigate whether there were socio-demographical differences between 
patients with ILI treated in general practice and OOH services during a pandemic 
(Paper II). 
Study III: (i) to explore how patients at risk for severe influenza used primary care 
services for ILI during the pandemic in comparison to low risk patients; and (ii) to 
investigate how patients with prior consultations with their GP used primary care 
services for ILI in comparison to patients who had no such consultations before the 
pandemic (Paper III). 
The published papers (Paper I, II and III) are later on referred to by their Roman 
numerals.  
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3. Materials and methods 
3.1 Design 
Study I is a cross-sectional study with patients in a general practice setting (Paper I). 
In collaboration with the research group, the chief municipal medical officer of each 
municipality mailed a letter to all GPs prior to the study, and they were requested to 
use ICPC-2 code “R80 Influenza-like illness” in their medical records when 
diagnosing a patient with influenza or ILI. For all other influenza-related contacts and 
questions to GPs’ offices, they were encouraged to use other diagnostic codes. GPs 
were asked to diagnose influenza in line with clinical recommendations and these were 
sent out. I visited all participating GP practices to ensure that the participating GPs 
comprehended in line with the study protocol. In addition, a paper with the diagnostic 
criteria of ILI was given in person to all participating GPs at the start of the study. A 
sample of the study participants (restricted to patients >18 years) who responded to a 
questionnaire were further included with data from a blood sample.                   
Study II and III are based on observational data from a national registry of billing 
claims (KUHR database; se below) (Paper II and III). Study II has a cross-sectional 
design. The design of the study reported in Paper III may be defined as a historical 
cohort because the exposure status of interest was recorded in the past and the 
outcome measured at a given time period later. The data in Study II and III were 
recorded prospectively, in real-time by the primary care doctors as a part of regular 
clinical work, and collected retrospectively by the researchers for analyses.  
3.2 Data sources 
Questionnares 
The data source in Study I was questionnaires from patients attending their GP and 
had an influenza diagnosis (ICPC-2 R80) in the period of October 26 to December 31 
2009. 
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The KUHR database 
The data source for Study II and III was the KUHR database with information 
extracted from billing claims from primary care doctors in Norway. 
All GPs in the regular GP scheme and all doctors at OOH services send electronic 
billing claims to HELFO for each patient contact to claim fee-for-services. Doctors 
working temporarily in the regular GP scheme or in OOH services are also obliged to 
send billing claims. The claims are registered in the KUHR database. The Norwegian 
Directorate of Health is responsible for KUHR. Claims that are paper-based are not 
included in this database. However, the KUHR database contains >95% of all claims 
for 2008 and 2009 (Nydal 2010).  
Variables in the data received from KUHR include: 
• Physician variables: person identifier, municipality, practice type. 
• Patient variables: person identifier, municipality, age, gender. 
• Date and time of contact. 
• Fees  
o Fees according to type of contact (consultation, home visit, telephone 
contact, multidisciplinary meeting). 
o Fees for diagnostic procedures, laboratory tests and other additional fees.   
• Diagnosis according to ICPC-2 (up to two diagnoses are recorded).  
3.3 Participants 
Study I (Paper I): GPs in the municipalities of Bergen (256,600 inhabitants), 
Austevoll (4,571 inhabitants), Lindås (14,286 inhabitants), Meland (6,631 inhabitants) 
and Kvam (8,360 inhabitants) were invited to participate in this study. In Bergen, we 
restricted the invitation to larger practices with three or more GPs due to logistical 
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reasons. In the other municipalities, we invited all GPs. Eligible patients were all 
individuals with the ICPC-2 diagnosis code “R80 Influenza/influenza-like illness”, 
identified from the primary care records of participating GPs in the study period 
(Figure 2).  
 
Figure 2. Flow chart of inclusion process of GPs and patients. 
All patients given an ILI diagnosis were sent a questionnaire 2-4 weeks after the first 
encounter with the GP’s office. After the study was finished, a manual search was 
performed in 15 of 55 GPs’ medical records to investigate the accuracy of the 
diagnostic procedures. This procedure revealed that 4 of these 15 GPs had applied the 
influenza diagnosis code (R80) inappropriately for the purpose of this study. 
Consequently, some individuals who did not have ILI received our questionnaire. The 
magnitude of this inaccuracy is difficult to decide.  
All patients >18 years of age receiving the questionnaire were also asked to volunteer 
to give a blood sample to measure serological response to A(H1N1)pdm09. Among all 
responders >18 years of age (251 patients; 70%), 186 patients volunteered for a blood 
test. If the patient did not give information about the date of sickness or did not donate 
a blood sample in the appropriate time window, then the patient was rejected from the 
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serology study (n=17). Flow chart for the inclusion process of the serology part of the 
study is given in Figure 3.  
 
Figure 3. Flow chart of cases with serological test; 72 cases were included 
for final statistical analyses. 
 
Study II (Paper II): All patient consultations registered in the KUHR database from 
two consecutive influenza seasons were included in the study. The threshold for 
influenza season, as defined by the Norwegian Institute of Public Health, is 1.4% ILI 
consultations per week. For the 2008-9 influenza season, this corresponds to week 1–9 
in 2009, and for the pandemic influenza season this corresponds to week 30–51 in 
2009. 
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Study III (Paper III): All patient consultations registered in the KUHR database from 
1 January 2008 – 31 December 2009 were included.  
3.4 Variables  
Study I 
In Study I, all patients where the diagnosis R80 was given in the GPs’ medical records, 
were eligible for the study and these were mailed the questionnaire, by the doctor or 
local secretary.   
The questionnaire (Appendix 1) was 4 pages long and was divided into the following 
sections: (i) self-reported symptoms of influenza including duration of symptoms; (ii) 
information about treatment, type of consultation and frequency of visit to health care 
providers as well as advice and preventive measures taken during the pandemic; (iii) 
history of seasonal and pandemic vaccination; statements concerning vaccination and 
influenza disease (pre-formulated motives/barriers) and (iv) demographics (age, 
gender, body weight in kg, height in cm, smoking habits, level of education, 
professional position, co-morbidities (cardiovascular disease, lung disease, diabetes, 
chronic renal disease, immunodeficiency, neurological disease) and for women; 
statement of pregnancy (yes/no). 
The research group, who has long combined experience with seasonal influenza from 
clinical work as GPs, developed the variables in the questionnaire. We listed 
symptoms of influenza to allow the patients to answer from the full panorama of 
possible symptoms.  
Eligible patients >18 years of age who volunteered to give a blood sample were 
included in the serology study. The blood sample was collected at the GP’s practice 
and sent to the Influenza Centre at the University of Bergen for analyses. The blood 
sample was collected 4–10 weeks after the first contact and analysed by the 
haemagglutination inhibition assay (HAI), which measures the specific serological 
A(H1N1)pmd09 response (Madhun 2010). The geometric mean haemagglutination 
inhibition titre was calculated for each subject and titres <10 were assigned a value of 
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5 for calculation purposes and considered negative. Samples with HAI titres ≥40 were 
considered seropositive and deemed protective. Titres of 10-39 were considered 
possible A(H1N1)pdm09 and excluded in statistical analyses.  
Study II and III 
In Study II and III the following HELFO variables were used: Patient’s age and 
gender, date of contact, type of contact (only claims containing a consultation were 
used) and diagnosis according to ICPC-2. In addition, the centrality of the patient’s 
municipality was recorded. Centrality was defined as a municipality’s geographical 
location in relation to a centre where there are important central functions and is 
measured on a scale of 0 to 3 where 0 is the least and 3 is the most central. 
In Study III we also included a person identifier (from KUHR database) allowing the 
utilisation of general practice and OOH services to be linked on the individual level. 
Patients belonging to a clinical risk group were defined in accordance to WHO 
definitions and are in line with national guidelines. In Paper III a clinical risk patient 
was defined if the patient had at least one consultation with the GP (in general 
practice) coded with the relevant and specific ICPC-2 codes at least one time in the 
pre-pandemic period (Week 1 2008 – Week 29 2009). Pregnancy was defined as 
having at least one consultation with the GP in the pandemic period (Week 30-51 
2009) with pregnancy specific ICPC-2 codes. Chronic renal disease was omitted due 
to lack of specific and relevant ICPC-2 codes to recognise such conditions (O'Halloran 
2004). The number of GP visits before the pandemic was categorised as 0,1,2,3,4-7 or 
≥ 8 consultations in the pre-pandemic period with the patients GP. 
3.4.2 Outcome variables 
Outcome variables in Paper I were self-reported duration and symptoms of influenza, 
treatment and hospitalisation (Appendix 1). Additional outcome variables in Paper I 
were statements about vaccination and influenza disease and adherence to personal 
protective measures. A sample of eligible patients was characterised according to 
results of serological testing. The outcome variable in Paper II and III was use of 
OOH services, with use of general practice as reference category.  
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3.4.3 Exposure variables 
Paper I: Exploration of symptoms among influenza patients without a specific 
exposure. For the subsample of patients with serology results, the exposure variable 
was ILI (ICPC-2 “R80”).  
In Paper II the exposure variable was having had a consultation with influenza 
diagnosis (ICPC-2 “R80”) as the result.  
In Paper III the exposure variables were 1) risk factors for severe influenza outcome 
and 2) the number of consultations with the GP in the pre-pandemic period among 
those patients diagnosed with ILI as the result. 
3.4.4 Confounding variables 
Confounding was not evaluated in Paper I per se, but results were given in strata to 
control for age and gender. In Paper II and III, potential confounding variables were 
age, gender and centrality. 
Age 
In Paper I, 82 out of 1324 invited patients and 2 out of 357 responders had missing 
information about. Age was presented in three groups: 0-17, 18-40 and >40 years 
based on the age span of the participants. Age was also dichotomised at 40 years of 
age based on the results of preliminary analyses. In Paper II, age was dichotomised to 
the age groups 0–20 years and >20 years in the frequency tables, based on the results 
of preliminary analyses. In the multivariate analyses, age was divided in three strata 
(0–20, 21–49 and 50 years and above) for testing of effect modification of age. In 
Paper III, age was divided into eight strata (0-4, 5-9, 10-14, 15-19, 20-29, 30-39, 40-
49 and ≥ 50 years of age) in the frequency tables. In the multivariate analyses, age was 
divided in five-year strata for testing of modification of age. All data included in 
Paper II and III contained valid information about age.  
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Gender 
In Paper I, 82 out of 1324 invited patients and 1 out of 357 responders had missing 
information about gender. All data included in Paper II and III contained valid 
information about gender. Gender was tested as an effect modifier in Paper II and 
III.  
Centrality 
In Paper II centrality were dichotomised to rural (centrality categories 0, 1 and 2) and 
urban (centrality category 3). In Paper III all categories of the centrality variable were 
included in the analyses. Effect modification was tested for this variable in Paper II 
and III.  
3.5 Analyses and statistical methods 
Both univariate and bivariate statistics were used to characterise the samples in all 
studies as well as stratified analyses where relevant. Chi-square tests were used to 
check for differences between groups. Effect modification was tested by the Breslow–
Day test for homogeneity between odds ratios (OR) after stratified analyses (Paper II 
and III). Confounding was evaluated by Mantel–Haenszel common odds ratios and 
logistic regression analyses (Paper II and III). Multivariate logistic regression 
analyses were performed to adjust for the confounders (Paper II and III).  
All tests were two-sided. P-values <0.05 were considered statistically significant in all 
analyses. ORs were presented with 95% confidence interval (CI).  
The statistical analyses were performed using SPSS Software version 17 (Paper I), 
version 19 (Paper II) and version 21 (Paper III). 
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3.6 Ethics 
Study I (Paper I) was approved by Regional Committee for Medical Research Ethics 
(project number 2009/1334). All patients who responded on the questionnaires 
provided written informed consent. For those below 18 years of age a guardian gave a 
written consent.  
The Norwegian Social Science Data Services approved the studies presented in Paper 
II and III, stating that the project was based on registry data from HELFO (project 
number 25159). The data that was delivered from HELFO was anonymous, and 
approval from the Regional Committee for Medical Research Ethics was not required.   
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4. Results 
4.1 Paper I 
Influenza-like illness in Norway: clinical course, attitudes towards vaccination and 
preventive measures during the 2009 pandemic 
The first study was a cross-sectional study in general practice based on patients with 
ILI during the peak of the influenza pandemic in Norway.  
Out of a list population of 63,808 (55 GPs), a total of 1324 patients were diagnosed 
with ILI in the 10-week-study period. Of these, 357 (27%) patients responded on the 
questionnaire. Median age was 32 years and 59% were females. Fatigue (94%), 
headache (79%), cough (77%) and myalgia/arthralgia (76%) were the most commonly 
reported symptoms among all participants. Fever and/or feverishness were reported in 
94% of patients, whereas fever alone (elevated temperature to >38°C) was reported by 
only 61%. The median duration of illness was 7 days; the median duration of specific 
symptoms varied from 2 to 8 days.  
Serological testing was performed in 83 patients (72 eligible for final analysis); 34 
confirmed positive and 38 confirmed negative for the A(H1N1)pdm09 virus. The most 
common symptoms for patients with confirmed H1N1 were fatigue (94%), cough 
(82%) and headache (76%). There were no statistically significant differences in 
symptoms between negative and positive A(H1N1)pdm09 groups.  
Women reported more use of cough hygiene (64% versus 51%, P = 0.015), hand 
washing (87% versus 73%, P < 0.01) and use of paper tissue (55% versus 34%, P < 
0.01) than men. Women were also more concerned about possible adverse effect of the 
vaccine than men (64% versus 45%, P < 0.01).  
Conclusions: Clinical symptoms of A(H1N1)pdm09 influenza were similar to seasonal 
influenza and difficult to discriminate from other upper respiratory tract infections. 
 47 
Women reported better adherence to personal protective measures than men and were 
also more concerned about possible side effects of the pandemic vaccine.  
4.2 Paper II 
Capacity and adaptations of general practice during an influenza pandemic 
This study was a registry-based study of all ILI consultations from primary care in 
Norway during the 2009 pandemic. The 2008-9 influenza season was selected for 
comparison (baseline season). Data was extracted from electronic billing claims from 
primary care doctors in general practice and OOH services.  
During the pandemic period 152,969 and 29,403 were consultations for ILI in general 
practice and OOH services, respectively. This constitutes a 3.3-fold increase of total 
ILI consultations compared to the 2008-9 influenza season. Younger age was 
associated with higher use of OOH services (26.1% in age group ≥20 years and 13.5% 
in age group <20 years). The pandemic period peaked in week 40 with 25% of all ILI 
consultations taking place in OOH services. This was in contrast to the 2008-9 season 
where only 10% of ILI consultations were conducted in OOH services.  
Conclusions: Most of the ILI consultations took place in general practice during the 
2009 pandemic; however, there was a 5.5-fold increase of ILI consultations in the 
OOH services during the 2009 pandemic season in comparison to the 2008-9 season. 
Low age was associated with the use of OOH services compared to general practice. 
GPs in Norway showed an ability to increase capacity during a pandemic.  
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4.3 Paper III 
Primary care utilisation among patients with influenza during the 2009 pandemic. 
Does risk for severe influenza disease or prior contact with the general practitioner 
have any influence? 
This study was a registry-based study of all patients diagnosed with ILI during the 
2009 pandemic in Norway. Patients belonging to risk groups were identified during an 
18-months period by diagnoses from GPs’ billing claims. 
Of 12,691 ILI patients in general practice and 2480 ILI patients in OOH services with 
clinical risk factors, patients with chronic lung disease and pregnancy comprised the 
largest risk groups. Being an ILI patient with at least one risk factor was associated 
with higher risk of attending OOH services (OR 1.50, 95% CI 1.42, 1.57). Pregnancy 
(OR 1.70, 95% CI 1.52, 1.89), diabetes mellitus (OR 1.68, 95% CI 1.49, 1.89), chronic 
lung disease (OR 1.44, 95% CI 1.34, 1.55) and cardiovascular disease (OR 1.42, 95% 
CI 1.23, 1.63) were risk markers associated with attending OOH services for ILI. 
Having any number of GP visits in the period before the pandemic (OR 0.84, 95% CI 
0.79, 0.90 for 1 consultation with the GP) was associated with a lower risk of 
attending OOH services for ILI during the pandemic. 
Conclusions: Pregnancy, diabetes and chronic lung disease were significant risk 
conditions for attending OOH services among patients with ILI during the pandemic. 
Contrary to this, having visited the GP before the pandemic was associated with lower 
use of OOH services.  
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5. Discussion 
5.1 Methodological considerations 
5.1.1 The design 
Paper I 
A major problem for studies on disease outbreaks is to obtain data prospectively as the 
outbreak emerges in the population. We managed to establish the research group and 
design for the first study before the pandemic reached epidemic threshold levels in 
Norway. Recruitment of GPs for the study was finalised at the time where the main 
pandemic wave began in Norway. Questionnaires were sent to eligible patients only a 
short time after contact with their GPs. This approach reduced the possibility of recall 
bias. For reasons due to logistics, time for planning, ethics approval and the 
recruitment process a cross-sectional design was decided for in Paper I. Due to lack of 
time it was not possible to do a pilot study or to validate the questionnaire used in 
Paper I. A major limitation with the design in this study was how the patients were 
included for the study. Eligible patients were those in whom the influenza diagnosis 
R80 was given in the medical records whether the influenza diagnosis was set during a 
simple contact with the office or during a consultation with the GP. This approach may 
have reduced the accuracy of the diagnosis. This was further confirmed by the manual 
search in GPs’ records where 4 out of 15 GPs (or, in many cases, their secretaries) had 
applied the diagnosis incorrect for our purpose. The diagnosis was used for situations 
such as influenza in the family, concerns about vaccination, etc. as well as own 
influenza symptoms. The inclusion process may have affected the response rate of the 
study in a negative direction, as some patients who did not have influenza, incorrectly 
received the questionnaire. For this reason, it is assumed that the true response rate 
among patients with influenza probably was higher than recorded.  
Paper II and III 
For Paper II and III we used national data from the KUHR database, which has 
considerable limitations with respect to the quality of the data material for research 
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purposes. Routinely collected claims data are not designed for research purposes. It 
contains no clinical data other than diagnoses. GPs and OOH services doctors 
generally send billing claims to HELFO to get paid. The economical motivation to 
send billing claims from patient activities in primary care is of course very strong and 
thus it is unlikely that doctors fail to report to HELFO. The KUHR database is very 
complete in documenting that a contact or consultation between a doctor and a patient 
has actually taken place and selection bias is thus unlikely to occur. A major concern 
with respect to data quality and accuracy is how diagnoses are reported. Specifically 
there is reason to be concerned about how simple contacts (not including a doctor) are 
reported. Claims from patient activities where the doctor has not been directly 
involved with the patients in his office (telephone calls to patients, letters or laboratory 
contacts without seeing a doctor) are omitted in Paper II and III because the chance 
of reporting inaccurate diagnoses is much more likely in such circumstances. When 
the doctor interacts with the patient in a face-to face consultation a medical history and 
regularly physical examination will be performed and hence the diagnosis has higher 
accuracy of describing the actual problem encountered. However, HELFO only record 
up to two diagnoses in the claims, and the majority of claims obtained for these studies 
(Paper II and III) contain only one diagnosis, thus reduced the possibilities to capture 
the full diagnostic works that is going on in the consultations. For example a patient 
can have both pneumonia and influenza, but only one of these diagnoses recorded in 
the claim.  
Observational studies are affected with limitations. The study design in Paper I and II 
was cross-sectional. Generally, caution should be made to interpret associations as 
causal relationship because exposure and outcome variables are recorded at the same 
time. Paper III was a historical cohort study, and because the exposures were 
recorded before the outcome, the temporal relationship may allow interpretations 
about causality, although other criteria for causality may not be fulfilled.    
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5.1.2 Risk of misclassification 
In epidemiology we recognise two different types of misclassification: differential and 
non-differential misclassification. Exposure, outcome and confounding variables are 
subject to risk of misclassification errors. For the outcome this may mean that a person 
who is classified with disease is incorrectly classified as without disease, and vice 
versa. The same counts for exposure and confounding variables. The correct 
classification depends on the accuracy of the measurement methods, i.e. the sensitivity 
and specificity of the diagnostic tool and the lack of information bias. Bias in 
estimating an effect can be caused by measurement errors in the needed information. 
Such a bias is called information bias (Rothman 2012a).  
One strength in this thesis is the low risk of recall bias: Participants in Paper I were 
given the questionnaires shortly after the contact with the GPs. Data used in Paper II 
and III were recorded prospectively in real-time by primary care doctors as a part of 
regular clinical work. 
Differential misclassification 
With differential misclassification, the misclassification differs according to the value 
of other study variables (Rothman 2012b). It means that the exposure variable relies 
on the level of the outcome variables or vice versa. It is possible that patients with a 
risk factor for severe influenza outcome (Paper III) had a higher chance of getting the 
ILI diagnosis than those without a risk factor. Risk patients who presented to primary 
care services with ILI symptoms were more likely to be prioritised to see with a doctor 
than low-risk patients, in line with the health authorities’ recommendations. 
Accordingly, differential misclassification of the disease (influenza) on the basis of 
exposure status (risk group) was probably present in Paper III. Reversely, there was 
no differential misclassification of the exposure on the basis of the disease. Exposure 
variables (clinical risk group and number of consultations in the pre-pandemic period) 
were recorded prospectively before the primary care doctor diagnosed ILI and no 
recall bias was likely to be present. Differential misclassification was probably not 
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present in Paper II, because we used practice type as outcome variable and ILI 
diagnosis as exposure variable.  
Nondifferential misclassification 
Nondifferential misclassification is misclassification that is unrelated to other study 
variables. The level of nondifferential misclassification of the disease depends on the 
diagnostic test’s sensitivity and specificity (Rothman 2012a). In the case of influenza, 
laboratory confirmation is the gold standard. This was performed for a subsample of 
patients who responded on the questionnaire in Study I. Cases of influenza were 
collected from GPs’ records (Paper I) and from claims data (Paper II and III). The 
clinical diagnosis of influenza has been found to have a sensitivity of 0.88 and 
specificity of 0.42 when the prevalence of influenza was high in the community 
(Michiels 2011). The clinical diagnosis of influenza reflects the reality of imperfect 
diagnostic capability and thus represents a potential source of misclassification. On a 
national level, it is difficult to know how primary care doctors used the influenza 
diagnosis (R80) when seeing a patient presenting with ILI. Alternative diagnoses such 
as “fever”, “upper respiratory tract infection” and “pneumonia” could also have been 
used as possible diagnoses when suspecting influenza. If this practice differs among 
primary care doctors in Norway, misclassification will be present. There is also a 
possible misclassification the other way around. ILI during the first wave of the 
pandemic was mainly due to rhinoviruses (Anestad 2011).   
Nondifferential misclassification of the exposure variables is a problem in Paper III. 
The clinical risk groups for severe influenza outcomes are well defined by the WHO 
and in national guidelines. We used a pragmatic search based on diagnoses from 
consultations with the GPs in the pre-pandemic period. The use of ICPC-2 from 
primary care records is a relevant proxy for defining chronic conditions (O'Halloran 
2004). Because we used routine data, our study shares the limitations of other studies 
using routine data, particularly reliance on the quality of clinical data and specifically 
diagnoses. Some risk groups are probably underreported. For example if some patients 
had their regular care supplied from specialists in the inclusion period, they are not 
identified as a risk patients during the pandemic period. They will then be falsely 
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categorised as non-risk patients. The problem with underreporting cases in clinical risk 
groups is that it may affect the associations found in the study. If underreporting has 
occurred, the associations reported will probably be weaker than reality. People with 
chronic diseases are frequent users of OOH services, and this is specifically so for 
those patients who are not familiar with their GP (Flarup 2014). We found that 14% of 
the patients with ILI who attended the primary care services were from risk groups. 
The number should be higher if underreporting has occurred. However, the problem 
with underreporting is probably limited due to the long inclusion period of 18 months. 
More than 67% of patients in Norway had at least one consultation with their GP in 
2009, and the number was even higher for older patients and those with chronic 
conditions (Hetlevik 2012).  
Some diseases are better defined in the ICPC-2 chapters than others. Cardiovascular 
diseases, chronic lung diseases (asthma and chronic obstructive pulmonary disease), 
diabetes, cancers, and several liver diseases and neurological diseases have specific 
diagnosis codes that are easy to identify in the primary care records. It is hard to 
believe that GPs give those diagnoses of chronic diseases by random or false grounds. 
Undiagnosed patients will of course not be detected, for example a person with 
recurrent coughs, wheezes and pneumonias who if tested by spirometry would have 
been diagnosed with an obstructive lung disease. Even though chronic renal failure is 
identified as a risk factor for severe influenza outcome, there exists no specific or 
generic ICPC-2 code to identify that condition (Barnett 2012). For that reason this risk 
factor was omitted in Paper III.  
Women who were pregnant during the pandemic period could have been detected with 
high accuracy if linking to the birth registry was available for the researchers. To come 
around that problem, we defined pregnancy when at least one ICPC-2 code specific for 
pregnancy was given by the GP in the pandemic period. Most women in Norway 
consult their GP several times during the pregnancy. Also, specific fees exist for 
prenatal consultations that increase the sensitivity of the diagnosis. Women who gave 
birth before they had the ILI diagnosis will be misclassified as belonging to a risk 
group in our study. Reversely, there is no reason to suspect that a high percentage of 
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women have been misclassified as non-pregnant by this inclusion method, due to the 
universal care delivered by GPs during pregnancy. So, the misclassification in this 
case would go in one direction. It means that associations concerning pregnancy as a 
risk factor for OOH services attendance may be weaker than reported in this study.  
Morbid obesity, defined as BMI≥40, was identified as a new risk factor for severe 
influenza outcome during the pandemic (Louie 2011). Persons with overweight (BMI 
25.0-29.9), or obesity (BMI ≥30.0) are found to have impaired immunity to influenza 
in experimental studies, thus posing a potential risk for severe influenza outcome in 
those individuals (Paich 2013). The two ICPC-2 codes used to identify obesity as a 
risk factor in Paper III do not correlate to a specific BMI-class. Also, persons with 
overweight and obesity are poorly documented and diagnosed in primary care records 
(Baer 2013). It is reason to believe that obesity as a risk factor is subject to 
nondifferential misclassification in one direction in this study. Due to underreporting 
of BMI and diagnosis of obesity in primary care medical record, the association 
reported will be diluted, i.e. the association in the population will be stronger than our 
reports.  
5.1.3 Selection bias 
Selection bias is a systematic error in a study that stems from the procedures used to 
select participants, which may influence study participation in a systematic way. This 
occurs when the association between exposure and the outcome differs for those who 
participate and those who do not participate in the study (Rothman 2012b). 
Participants were included based on contact with the GPs’ office (Paper I) or 
attendance at the GPs’ office and/or OOH services (Paper II and III). The 
composition of the study groups will depend on individuals’ health seeking behaviour 
and the information recorded in the primary care records. Individuals with minor 
symptoms are less likely to seek medical help and a selection bias according to 
severity is reasonable to suspect (Bilcke 2014). Firstly, not all cases that were infected 
with influenza develop symptoms of disease. Secondly, not all with symptoms of 
influenza seek medical care. And thirdly, not all who seek medical care see a doctor 
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and eventually receive the influenza diagnosis. During the pandemic, different 
measures were addressed to the public to avoid pressure on the primary care services. 
These included the use of extended self-certification of sick leave and the release of 
oseltamivir as over-the-counter drug. And finally, the risk of getting the influenza 
diagnosis by a primary care doctor depends on the capacity of primary care services to 
admit new patients who seek medical care during an outbreak. Almost 75% of all 
contacts in Norwegian OOH services ended without a consultation with a doctor 
(Press 2010). Those who are otherwise healthy (including young persons) and people 
with no underlying clinical risk group are possibly underestimated when only those 
who attended primary care services are counted (Sauro 2006). And opposite, people 
with a clinical risk factor, the elderly, and especially those who regularly attend 
primary care, as well as those with moderate to severe symptoms are more likely to 
consult a doctor (Bilcke 2014).  
The composition of included participants will be influenced by the response on the 
questionnaire (Paper I). Among all invited participants in the study reported in Paper 
I, only 27% responded. We did not have information about non-responders, so it is 
difficult to say if the groups of responders and non-responders differ in any respect. A 
selection bias according to age is suspected in Paper I because of skewed age 
distribution towards older age in our study compared to laboratory-confirmed cases of 
influenza in Norway (Norwegian Institute of Public Health 2009b). Children are less 
likely to respond to questionnaire studies if not assisted by an adult. Also, it is difficult 
to report symptoms from the youngest ones. In Paper II and III all cases were 
included and selection bias on this level was not a problem.  
5.1.4 Internal validity and generalisability 
The validity of a study is usually divided into two components: Internal and external 
validity. Internal validity is sensitive to systematic bias, such as confounding, selection 
bias and information bias. Strong internal validity is lack of systemic errors and is a 
prerequisite for external validity and for the results to be generalisable outside the 
source population (Rothman 2012a). In Paper I, the low response rate and hence 
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possible selection bias threatens the internal validity and thus pose a problem with 
generalisability. Due to aforementioned concerns, the ability to use the study as a 
prevalence study is thus also weakened. Information bias is probably also present due 
to misclassification of the disease (influenza). In the case of the serology part, eligible 
patients were tested with a gold standard influenza test and information bias was 
probably not present. We interpret that the internal validity of describing symptoms of 
patients from general practice with a confirmed influenza diagnosis as strong. 
Paper II and III are both subject to misclassification errors, however selection bias 
was not present in those studies and plausible confounding was controlled for by 
multivariate regression analyses. The data are very complete on a national level and 
the representativeness is high. Results from studies reported in Paper II and III are 
generalisible to countries with a similar primary care system as Norway. They cannot 
be generalised to countries with a very different health care system where specialist 
services take a more central place, or in health care systems where referrals are not 
mandatory.  
5.1.5 Effect modification 
Effect modification refers to a situation in which a measure of effect changes over the 
value of some other variable (Rothman 2012b). In Paper II we found a significant 
effect modification for age and gender on the effect of diagnosis on practice type, as 
significantly higher ORs for ILI diagnosis were found for males and age group >50 
years for these exposures. When effect modification is present, results should be given 
in strata. Men and younger people were significantly more often attended OOH 
services during the pandemic compared to women and those in age group ≥50 years. 
In Paper III, effect modification was statistically significant for centrality on the 
association between three risk factors (chronic lung disease, diabetes mellitus and “any 
risk factor”) on the use of OOH services, as significantly higher ORs were found for 
these three exposures in more central areas than in rural areas. 
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5.2 Discussion of the results 
5.2.1 Influenza attack rates 
The influenza pandemic caused a substantial demand on the primary care services in 
Norway. Out of a population of 4.8 millions inhabitants (2009), ∼2% received an ILI 
diagnosis in general practice during the pandemic (Table 2).  
Table 2. Proportion of ILI in general practice in Norway during the 2009 pandemic 
Source Type of cases §Source 
population (N) 
ILI cases (n) Proportion (%) 
Paper I ILI contacts 63,808 1,324 2.1 
Paper II ILI consultations 5,442,624 104,168 1.9 
Paper III ILI patients 4,799,252 94,404 2.0 
 §Source population is defined as the total number of ILI in general practice for the 
three respective studies. Paper III: Population in Norway per 1.1.2009 
Corresponding number for OOH services is given in Table 3. ILI consultation rate was 
4.6% and 0.4% of the population had a consultation in the OOH services due to ILI. 
Table 3. Proportion of ILI in OOH services in Norway during the 2009 pandemic 
Source Type of cases §Source 
population (N) 
ILI cases (n) Proportion (%) 
Paper II ILI consultations 496,529 22,632 4.6 
Paper III ILI patients 4,799,252 17,738 0.4 
 §Source population is defined as the total number of ILI consultations in OOH 
services and for Paper III: Population in Norway per 1.1.2009 
For the 2008-9 season, the ILI consultation rate was 1.5% in general practice and 1.9% 
in OOH services respectively (Paper II). 
The Norwegian Institute of Public Health has estimated that 900,000 individuals were 
infected during the 2009 pandemic in Norway, which gives a national infection rate of 
19% (Kacelnik 2011). This gives consultation incidence rates among the infected of 
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10.5% in general practice and 2.0% in OOH services, when using the national estimate 
as the denominator. As of January 2010, 59% of a representative population sample 
had detectable antibodies to the A(H1N1)pdm09 virus either due to infection or 
immunisation and 44.9% of the sample had protective values (HI titre ≥40) (Waalen 
2010). The sentinel GPs in Norway reported an average ILI consultation rate of 4.5% 
in the pandemic period (week 30-51 2009) (Norwegian Institute of Public Health 
2009a). This number is higher than we found (Table 1). A possible explanation of this 
inconsistency in figures could be due to more precise definition of ILI among sentinels 
GPs. Sentinel GPs have years of experience with reporting ILI and are encouraged to 
use the ICPC-2 code “R80” restricted for cases of clinical influenza (Gran 2010). So, 
there are reasons to believe that GPs on a national level report ILI in their billing 
claims using several different diagnoses from the ICPC-2 chapters, for example “A03 
Fever”, “R78 Upper respiratory tract infection” and more. When we take a look at all 
GP consultations from the peak of the main pandemic wave, but exclude the 
consultations with diagnosis R80 (Figure 4) we observe a peak in week 44 that 
corresponds well to the peak of ILI in Norway. Such a peak is not observed in the 
same weeks for 2008 (data not shown). This gives evidence to our concerns about the 
method of identifying ILI cases from billing claims. An alternative interpretation of 
the peak observed in Figure 4 could represent a true increase in non-influenza 
consultations in general practice. This is supported by the fact that our method of 
identification of ILI, in line with the new primary care influenza surveillance based on 
claims data seems to follow the same patterns as the current sentinel GP surveillance 
system (Hauge 2014). Also, claims-based ILI is found reliable in USA for capturing 
influenza activity in the population (Viboud 2014).    
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Figure 4. Consultations per week in general practice in Norway during week 
40-48 2009 excluding diagnoses with ICPC-2 code “R80 influenza”.  
 
In China the annual incidence rate of outpatients ILI was 19.2 per 1000 population in 
2009 (Guo 2012). The clinical attack rate in USA was 20% (Shrestha 2011) and only 
5% in Denmark (Molbak 2011). In contrast to many countries in Europe, Norway 
experienced much higher number of ILI cases during the pandemic compared with the 
preceding epidemic seasons (Meeyai 2013). Reasons for this heterogeneity in number 
of ILI cases and high number of ILI cases in several countries are not known. It is 
discussed by Meeyai et al. that countries with improved public communication 
systems encouraged possible cases to seek medical attention thus explaining the higher 
ILI rates in some countries, including Norway.  
5.2.2 Primary care utilisation 
Utilisation according to age (Paper II and III) 
The first papers on the novel influenza virus reported a skewed age distribution 
towards younger age compared with seasonal influenza, where mostly elderly is 
infected (Cao 2009, Dawood 2009, Dominguez-Cherit 2009, Kumar 2009). The 
median age was 20-44 years in those aforementioned papers. We found a median age 
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of 29.4 years during the pandemic period and a median age of 36.5 years in ILI 
patients in the 2008-9 season (Paper II). During the pandemic, 43.9% of ILI patients 
were below 20 years of age, and only 10.4% were ≥50 years of age. In general 
practice, 29.0% were below 20 years of age and 15.9% were ≥50 years of age (Paper 
III). Among all ILI patients, there was a tendency for the youngest ILI patients to use 
OOH services more than their older counterparts (26.1% in age group ≤20 years and 
13.5% in age group >20 years) (Paper II). The high utilisation of OOH services 
among young patients during the pandemic was expected as young children (0-9 
years) have the highest contact rates in Norwegian OOH services (Hansen 2009). 
Also, the clinical attack rates were highest among children and young adults due to no 
previous immunity to the A(H1N1)-like viruses (Miller 2010, Waalen 2010). 
According to Poehling et al., children (0-5 years) had 10-250 times as many influenza-
related outpatient consultations than hospitalisations during two consecutive influenza 
seasons thus representing a major burden on the primary care services (Poehling 
2006).  
To further evaluate young age as an independent risk factor for attending OOH 
services with ILI during the pandemic, I performed additional multivariate regression 
analyses with practice type as outcome variable (reference variable: general practice) 
and age dichotomized at 20 years of age as exposure variable (reference variable: ≥20 
years of age). This gave an unadjusted OR = 1.91 (95% CI 1.85, 2.00) and an adjusted 
OR = 1.45 (95% CI 1.41, 1.56) when controlling for gender, centrality and clinical risk 
groups (“any risk”). In conclusion, young age (<20 years) was an independent risk 
factor for attending OOH services compared to general practice for ILI during the 
pandemic.       
Utilisation according to risk groups (Paper III) 
We found that pregnancy, diabetes, chronic lung disease, and cardiovascular disease 
were risk factors that were statistically significantly associated with attending the 
OOH services among patients with ILI. Also ILI patients with neurological disease 
and conditions associated with immune deficiency (including cancers) had increased 
risk of attending OOH services. However, the associations found were weak. The 
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increased risk of attending OOH services may reflect a real increased risk among those 
belonging to a risk group. Alternatively, it may reflect a higher likelihood of getting an 
influenza diagnosis recorded because such patients are more likely to use the OOH 
services on a regular basis or because they are more careful about their health and 
more likely to report fever and other flu symptoms to the doctor. In a British study, 
factors like fear, anxiety or if the condition was felt urgent were associated with 
increased OOH service use (Drummond 2000). The increased attention in national 
newspapers about the pandemic and its possible serious consequences could have led 
to higher OOH utilisation among people at risk (Lundh 2009) and especially for those 
who were pregnant during the pandemic (Fjellheim 2009). People with chronic 
diseases are frequent attenders both in general practice and OOH services, and they 
have higher rates of hospitalisation (Glynn 2011). A large cross sectional study from 
Danish OOH services found that 30% of adult patients contacting OOH services were 
by people with chronic diseases, in which cardiovascular disease, diabetes and cancer 
constituted the largest groups. People with chronic diseases were more likely to 
receive a face-to-face consultation (Flarup 2014). In light of the advice from the 
Norwegian health authorities where patients at increased risk of severe outcomes 
should be prioritised in primary care services, we can conclude that the OOH services 
seemed to prioritise in accordance with the advice.  
Utilisation according to number of consultations with the GP in the pre-
pandemic period (Paper III) 
One of the aims was to investigate the relationship between GP visits before the 
pandemic and utilisation of primary care during the pandemic. This study tests the 
hypothesis that continuity of GP care protects against using the OOH services for an 
acute illness such as influenza. Our study showed that having at least one consultation 
prior to the pandemic was associated with lower risk of attending OOH services for 
ILI as compared to attending the GP. Reversely, no GP consultation history was 
associated with OOH service utilisation for ILI during the pandemic. Continuity of 
care has two important dimensions; longitudinality and intensity (Hansen 2013). The 
former is describing the duration of doctor-patient relationship and the latter is 
describing intensity of visits. According to two studies from Norwegian general 
 63 
practice, only longitudinality was associated with reduced specialist care and higher 
patient satisfaction. High frequency of visits was associated with presence of chronic 
diseases and with increased probability of specialist use (Hansen 2013, Hjortdahl 
1992). In our study, the exposure variable was number of consultation with the GP in 
an 18-months period prior to the pandemic. Whether this approach was a good 
surrogate for longitudinality of care or intensity of care, or perhaps a mixture of both, 
can be discussed. Our results suggest that continuity of care could possibly reduce the 
use of OOH services during a pandemic.  
5.2.3 Primary care capacity (Paper II) 
The capacity of a primary care system depends on several factors including available 
doctors in general practice and OOH services, total hours available for patient 
appointments, waiting time and booking preferences.  
Influenza epidemics are expected to put extra pressure on the primary care services 
(Bocquet 2010, Pitman 2007). In Paper II we compared the 2008-9 influenza 
epidemic to the 2009 pandemic in terms of consultations volume during both influenza 
periods. Respectively, 10.7% of ILI consultations in the 2008-9 season and 17.8% ILI 
consultations in the pandemic period were conducted in the OOH services. This 
constituted a 5.5-fold increase of ILI consultations in the OOH services during the 
2009 pandemic season. Comparing the utilising pattern of these two periods sheds new 
light on the interaction between OOH services and general practice during a period 
with increased patient load. The pandemic period looked quite similar in the start of 
the 2008-9 season: About 1/10 of ILI consultations were conducted in the OOH 
services. This proportion held through the whole 2008-9 season. When the pressure on 
the primary care increased during the pandemic autumn wave, the ILI consultation 
proportion changed substantially towards a higher proportion of OOH service 
consultations. At the peak, 25% of all ILI consultations were conducted in OOH 
services, compared to 10% on average during a regular season. This change in 
proportion between primary care services can be expressed as a mechanism of 
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adaptation in which OOH services adapted by increasing the capacity for ILI to the 
benefit of other encounters (Figure 5). 
 
Figure 5. ILI consultations in general practice and OOH services during 
2008-9 influenza season (week 1–9 2009) and pandemic influenza season 
(week 30–51 2009)(Paper II). 
 
In absolute numbers, however, general practice had the largest capacity due to 
substantially more doctors working compared to the OOH services. Additionally, the 
capacity for non-influenza consultations was increased in general practice during the 
autumn pandemic wave (Figure 4) so that the total capacity for consultations 
increased. In the OOH services the total capacity was unchanged compared to pre-
pandemic phase so that non-influenza consultations decreased to the benefit for 
influenza patients. Increasing the primary care capacity during outbreaks of emerging 
infectious diseases is an important step in first line preparedness and may prevent 
unnecessary hospital admissions (Bocquet 2010, Lurie 2009). 
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5.2.4 Clinical characteristics of influenza-like illness (Paper I) 
There are few published papers on the clinical characteristics of influenza from 
patients consulted in general practice (Michiels 2011, Sessa 2001, van Elden 2001). 
Regarding pandemic influenza, two reports from general practice were restricted to 
children and teenagers (Hawkes 2011, Nitsch-Osuch 2010) and only one study 
described clinical features of patients with influenza from a primary care setting 
during the pandemic without restriction to a specific age group (Duque 2011). Among 
the laboratory confirmed influenza cases in Paper I, fatigue (94%), cough (82%), 
headache (76%) and fever (56%), were the most common symptoms. This is 
comparable with the results from Nitsch-Osuch et al. and Dugue et al. except that 
fever was reported in a lower percentage among our cases. However, 97% of 
confirmed cases reported fever and/or feverishness in our study. Also, longer periods 
of cough and illness duration (median length 9 days) were reported among confirmed 
cases compared to those with negative tests (Paper I).  
Treatment with oseltamivir was reported in 140 patients (39%) in Paper I, and was 
significantly associated with the age group ≤40 years. However, this treatment did not 
affect the duration of symptoms of influenza disease compared to patients not 
reporting such treatment. In a recent systematic review on oseltamivir treatment, this 
was found to reduce symptoms in adults by 16.7 hours (Jefferson 2014b). Only two 
patients in our study reported hospitalisation, both patients belonging to a clinical risk 
group, thus reflecting the mild appearance of the A(H1N1)pdm09 virus. To conclude, 
symptoms of pandemic influenza were similar to seasonal influenza symptoms, 
findings in line with others (Belongia 2010, Shiley 2010).  
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5.2.5 Self-reported adherence to precautionary behaviours (Paper I) 
Participants in Paper I reported high level of adherence to personal protective 
measures. This study was conducted when the pandemic peaked in Norway and 
simultaneously with the campaign launched by the health authorities for better 
hygiene. The campaign focused on cough and hand hygiene as an infection preventive 
measures against influenza. In the same period there were reduced contact rates for 
infectious diseases to OOH services (Sandvik 2011). The results suggest that the 
campaign was effective (Paper I, Sandvik 2011). We found a strong correlation of 
adherence to advice with female gender. Women were more likely to adhere to cough 
etiquette and applied hand washing more often than men. We found no gender 
differences concerning social distancing or use of hand disinfectant and the use of face 
masks. Also, there were no differences in preventive measures according to age. 
Frequent hand washing was associated with female gender among health care workers 
(La Torre 2009, Savas 2010) and in the general population in Hong Kong (Cowling 
2010a, Lau 2010) and China (Lin 2011). A study from a primary care clinic in 
Malaysia did not find gender differences in practices regarding hand washing and 
similar measures; however a positive attitude towards preventive measures was 
significantly associated with female gender (Latiff 2012).  
5.2.6 Attitudes towards influenza vaccination and disease (Paper I) 
A positive attitude to vaccination of the whole population against A(H1N1)pdm09 was 
reported by the majority of participants in Paper I. The perceived risk of getting 
influenza was, however very low. This finding is puzzling as the responders’ were 
selected from patients who had recently experienced influenza. Only ¼ of responders 
would consider influenza vaccination the succeeding year. A negative attitude towards 
the influenza vaccine in general and regarding the pandemic vaccine was associated 
with female gender and age >40 years (Paper I). Toh et al. reported similar findings 
concerning attitudes towards pandemic vaccination among health care workers in 
primary care clinics in Singapore (Toh 2012). Concerns about pandemic vaccine side 
effects were also associated with female gender but with age ≤40 years. Fewer 
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concerns were reported for the seasonal vaccine than for the pandemic vaccine. Our 
study suggests that there were some misunderstandings in the public concerning risk 
and safety of influenza vaccine and influenza disease. More effort from the health 
authorities should be taken in order to improve communication about vaccine safety 
and risk as well as the general knowledge about influenza (Dedoukou 2010, 
Aavitsland 2014).  
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6. Conclusions 
This thesis contributes to the present knowledge about the 2009 influenza pandemic 
viewed from a primary care perspective.  
We found that clinical characteristics of the novel A(H1N1)pdm09 influenza were 
similar to seasonal influenza except for a skewed age curve towards younger people.  
Women reported better adherence to precautionary behaviour during the pandemic 
than men and were more concerned about side effects of the pandemic vaccine. 
The primary care services were exposed to a significant increase in the number of 
consultations during the pandemic as compared to a seasonal influenza epidemic. 
Primary care services in Norway showed the ability to increase capacity and prioritise, 
according to authority advice during a period of increased patient surge. Young age 
was associated with increased risk of attending OOH services. 
Clinical risk groups for severe influenza outcome, and especially those being pregnant 
during the pandemic or suffering from diabetes, chronic lung diseases or 
cardiovascular diseases, had an increased risk of attending OOH services with ILI.  
Continuity of GP care in terms of having had consultations prior to the pandemic was 
associated with lesser risk of attending OOH services with ILI during the pandemic. 
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7. Future research 
During the last decade we have witnessed outbreaks of avian influenza, Severe 
Acquired Respiratory Distress (SARS), Middle East Respiratory Syndrome (MERS) 
and currently the devastating Ebola outbreak in Africa, all showing that surveillance, 
research and global action are needed to control infectious diseases.   
Influenza viruses are driven by continuous change in its genetic material to cause 
seasonal epidemics and occasional pandemics. Primary and community health care 
services are in most countries the first line of care for people suffering from influenza. 
Substantially fewer are in need of hospital care. However, much of the current 
knowledge about influenza is derived from hospital and experimental research.  
Primary care is a field where knowledge is highly needed and still lacking the most. 
More efforts should be done to study the clinical features of influenza in patients 
seeking primary care, and specifically for those belonging to a risk group.  
Clinical research in general practice is difficult with respect to logistics, especially 
with regard to the process of recruitment of doctors and patients at a time when things 
must happen quickly such as during epidemics. Primary care research networks may 
be a step to change this situation (Rortveit 2014).  
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